Endolastic

Executive Summary

Endolastic is a privately held medical device company based in Austin, Texas, developing the EndoBand™ platform, a minimally invasive ligation-based system for endoscopic tissue management. The platform targets three major metabolic conditions: gastroesophageal reflux disease (GERD), obesity, and type 2 diabetes. Endolastic's procedures are designed as quick, outpatient interventions that leverage the body's natural healing response to promote tissue regeneration, potentially offering a less invasive alternative to existing surgical and device-based therapies. Founded in 2017, the company has not disclosed total funding or valuation, but its focus on high-prevalence metabolic diseases positions it in a large and growing market. Endolastic's technology could address significant unmet needs by providing a low-risk, repeatable, and cost-effective solution for patients who are not candidates for or wish to avoid more invasive procedures. Early clinical data and regulatory progress will be critical for validating the platform's safety and efficacy across its target indications.

Upcoming Catalysts (preview)

• Q2 2026Initial clinical data from GERD feasibility study70% success
• H2 2026Series A or B financing round60% success
• Q1 2027FDA 510(k) clearance or IDE approval for obesity trial50% success